Astrazeneca Pharma

AstraZeneca Pharma India received permission from India’s drug regulator to import and sell Enhertu (trastuzumab deruxtecan) for an additional indication covering neoadjuvant treatment of HER2-positive Stage II or III breast cancer. Enhertu is one of three oncology products that have driven the company’s revenue growth in recent years. In the year to March 2026, revenue rose 33% to ₹22,756 million, with oncology contributing roughly 75% of product sales. The company secured 11 regulatory approvals in FY26 and operated debt-free with net cash of ₹4.5 billion.

Powered by Tijori

July 28 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA - RECEIVES PERMISSION TO IMPORT AND SELL TRASTUZUMAB DERUXTECAN FOR ADDITIONAL INDICATION

Source text: ID:nBSE744v9g

Further company coverage: ASTR.NS

(([email protected];;))

July 21 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA - BHAVANA AGRAWAL RESIGNS AS CFO EFFECTIVE AUGUST 31, 2026

Source text: ID:nBSEbZMPhT

Further company coverage: ASTR.NS

(([email protected];))

AstraZeneca Pharma India obtained permission from the Central Drugs Standard Control Organisation to import and market Benralizumab, branded as Fasenra, for an additional indication — Hypereosinophilic Syndrome (HES) in patients aged 12 years and older without an identifiable non-haematologic secondary cause. The July 15, 2026 approval covers the 30 mg/ml solution for injection in a pre-filled syringe. The drug, which depletes eosinophils, is already used globally for severe eosinophilic asthma; the new indication targets a rare disorder characterised by elevated eosinophil counts. AstraZeneca stated that the permission enables the launch of Fasenra for HES in India, subject to related statutory approvals.

Powered by Tijori

July 16 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA - RECEIVES PERMISSION TO IMPORT BENRALIZUMAB (FASENRA) FOR ADDITIONAL INDICATION

Source text: ID:nBSE4Rs2Sz

Further company coverage: ASTR.NS

(([email protected];))

AstraZeneca Pharma India received permission from India's drug regulator to import and market its antibody-drug conjugate Trastuzumab deruxtecan, sold as Enhertu, for a new indication: first-line treatment of unresectable or metastatic HER2-positive breast cancer in adults, in combination with pertuzumab. The approval from the Central Drugs Standard Control Organization expands the drug's eligible patient pool in India beyond any previously cleared indications. Enhertu is a globally established therapy that generated over $3 billion in sales worldwide in the last financial year. The company said the permission paves the way for marketing the drug for the specified indication, subject to any related statutory approvals.

Powered by Tijori

June 11 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA - RECEIVED PERMISSION TO IMPORT FOR SALE OF TRASTUZUMAB DERUXTECAN

Source text: ID:nBSE6vFWJS

Further company coverage: ASTR.NS

(([email protected];))

** Biopharma company Astrazeneca Pharma India's shares ASTR.NS fall as much as 6.76% to 8,357 rupees apiece

** This is stock's steepest intraday decline in two months

** ASTR posts a 23% year-on-year drop in March quarter profit; operating profit slips 29.5%

** Stock is most active in six weeks, with a trading volume of 35,516 shares as of 12:17 p.m. IST, more than quadruple the 30-day average volume, data compiled by LSEG shows

** ASTR shares are down 5.8% in 2026 so far, according to exchange data

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

May 26 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA LTD - RECOMMENDS DIVIDEND OF 36 RUPEES PER EQUITY SHARE FOR FY2025-26

Source text: ID:nBSEbBnmHB

Further company coverage: ASTR.NS

(([email protected];))

March 17 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES PERMISSION TO IMPORT DURVALUMAB (IMFINZI) FOR ADDITIONAL INDICATION

Source text: ID:nBSE4YQpNZ

Further company coverage: ASTR.NS

(([email protected];;))

Feb 11 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA DEC-QUARTER PAT 325.9 MILLION RUPEES

• ASTRAZENECA PHARMA INDIA DEC-QUARTER REVENUE FROM OPERATIONS 6.12 BILLION RUPEES

Source text: ID:nBSE5MKvG0

Further company coverage: ASTR.NS

(([email protected];))

Feb 10 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA LTD - RECEIVES PERMISSION TO IMPORT DURVALUMAB

• ASTRAZENECA PHARMA - PERMISSION PAVES WAY FOR MARKETING OF DURVALUMAB SOLUTION IN INDIA

Source text: ID:nBSE4kw3HB

Further company coverage: ASTR.NS

(([email protected];))

Sept 12 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA - GETS SHOW CAUSE NOTICE FROM NATIONAL PHARMACEUTICAL PRICING AUTHORITY

• ASTRAZENECA PHARMA INDIA LTD - NPPA ALLEGES OVERCHARGING FOR 'SYMBICORT TURBUHALER'

• ASTRAZENECA PHARMA INDIA LTD - CLAIM QUANTUM 605 MILLION RUPEES

Source text: ID:nNSEb5xzyw

Further company coverage: ASTR.NS

(([email protected];))

Sept 2 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• SURRENDERS MANUFACTURING LICENSE

Source text: ID:nBSE3qVVyp

Further company coverage: ASTR.NS

(([email protected];))

Aug 14 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• JUNE-QUARTER PAT 558.3 MILLION RUPEES

• JUNE-QUARTER REVENUE FROM OPERATIONS 5.26 BILLION RUPEES

Source text: [ID:]

Further company coverage: ASTR.NS

(([email protected];;))

June 26 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA: EXPANDS BANGALORE GLOBAL HUB IN INDIA WITH 1.66 BILLION RUPEES INVESTMENT

Further company coverage: ASTR.NS

(([email protected];))

June 9 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA LTD - SANJEEV KUMAR PANCHAL HAS OFFERED TO RESIGN AS MD

Source text: [ID:]

Further company coverage: ASTR.NS

(([email protected];))

** AstraZeneca Pharma India ASTR.NS shares up 11.5% at 8,885 rupees, marking their biggest pct jump so far this year

** ASTR on Friday reported 48% surge in Q4 profit on strong performance of oncology and biopharma divisions

** AstraZeneca shares up 21.6% YTD vs 8.8% fall in Nifty pharma index .NIPHARM

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected] ))

May 29 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES PERMISSION TO IMPORT OSIMERTINIB TABLETS

Source text: ID:nNSE5r4vcG

Further company coverage: ASTR.NS

(([email protected];;))

May 8 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES APPROVAL FOR ENHERTU IN INDIA

Source text: ID:nNSEXz4FK

Further company coverage: ASTR.NS

(([email protected];;))

April 15 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• SURRENDERS MARKETING AUTHORISATION FOR OLAPARIB TABLETS

• DISCONTINUATION DUE TO COMMERCIAL REASONS, NOT EFFICACY OR SAFETY

• HOLDS ALL OTHER PERMISSIONS FOR OLAPARIB IN INDIA

• NEVER MARKETED OLAPARIB INDICATION IN INDIA

Source text: ID:nBSE1YlFfg

Further company coverage: ASTR.NS

(([email protected];;))

March 28 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• DISCONTINUING MANUFACTURING, MARKETING OF PROLONGED RELEASE ISOSORBIDE-5-MONONITRATE TABLETS BP

Source text: [ID:]

Further company coverage: ASTR.NS

(([email protected];))

** AstraZeneca Pharma India ASTR.NS rises 2.1% to 7,622.9 rupees, highest in about a month

** Biopharmaceutical co receives Indian drug regulator's permission to import Durvalumab solution for sale, distribution

** Drug is used to treat patients with a certain type of lung cancer

** Shares trading above 50-, 100-, 200-day moving avg

** ASTR up 2.2% YTD, after gaining 32% in 2024

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

March 7 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES PERMISSION TO IMPORT DURVALUMAB SOLUTION

• PERMISSION PAVES WAY FOR MARKETING DURVALUMAB SOLUTION IN INDIA

Source text: ID:nNSEb26vVv

Further company coverage: ASTR.NS

(([email protected];;))

March 6 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES PERMISSION TO IMPORT PHARMACEUTICAL FORMULATIONS OF LOKELMA

Source text: ID:nNSE5FXNVQ

Further company coverage: ASTR.NS

(([email protected];;))

** AstraZeneca Pharma ASTR.NS rises 2.7% to 6,872.1 rupees; stock's biggest one-day gain since Feb. 3

** Biopharmaceutical co receives Indian drug regulator's permission to import Durvalumab solution for sale, distribution

** Drug is used to treat patients with a certain type of liver cancer

** Shares mark second-busiest session in about 2 weeks, with more than 11,000 shares traded

** Stock down 8% so far this year, after a 32% gain from 2024

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Feb 28 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES PERMISSION TO IMPORT DURVALUMAB FOR ADDITIONAL INDICATION

• GETS PERMISSION FROM CENTRAL DRUGS STANDARD CONTROL ORGANISATION, INDIA

Source text: ID:nNSE3QqT8W

Further company coverage: ASTR.NS

(([email protected];;))

** Astrazeneca Pharma India ASTR.NS rises 2% to 7,609 rupees

** Q3 profit before exceptional item and tax jumps ~3.7x y/y, helped by strong demand for its oncology products; rev up 44%

** Co incurred one-off 335.5 million rupees ($3.9 mln) employee separation cost in the quarter

** More than 41,000 shares traded, 1.5x the 30-day avg

** Stock rose 32% in 2024

($1 = 86.8200 Indian rupees)

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

BENGALURU, Feb 11 (Reuters) - Diary of India economic, corporate events on Feb 11

ECONOMIC, CORPORATE .BSE500 EVENTS:

NTS - 'No time scheduled'

(Compiled by Bengaluru Newsroom)

(([email protected]))

LONDON, Feb 6 (Reuters) - Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it scrapped plans to build a 450 million pound ($558.86 million) vaccine plant because of a cut to government support.

Prime Minister Keir Starmer's plan to stimulate growth in Britain's stagnant economy by attracting business investment was given a painful reality check last week when AstraZeneca, the country's most valuable listed company, cancelled the expansion of an existing facility in Speke, northern England.

The chief executive of AstraZeneca said Britain needed to offer better incentives to secure investment, highlighting the "very competitive world" in which companies operate.

"The UK needs to continue working on improving the investment environment to attract investment," CEO Pascal Soriot told reporters as the company announced annual results on Thursday.

He said AstraZeneca was offered "substantial support" by other governments, like Singapore, to build facilities.

For its part, Britain blamed AstraZeneca for scaling back its research and development plans for the now cancelled expansion, which would have made next-generation vaccines. As a result, the finance ministry cut the support on offer.

AstraZeneca said it remained "very committed" to Britain despite pulling the Speke plan and is spending 200 million pounds expanding its Cambridge site.

"We as a company continue to work very closely with the government to support the life sciences strategy to try and improve the overall environment, to attract investment," Soriot said.

He said the lower level of government support meant the business case for Speke no longer worked. Science department minister Chris Bryant said earlier this week the difference in funding between what was originally offered and the final proposal was "remarkably small".

($1 = 0.8052 pounds)

(Reporting by Maggie Fick and Pushkala Aripaka, Writing by Sarah Young; editing by William James)

(([email protected]; +44 20 7542 1109; Reuters Messaging: [email protected]))